U.S. futures subdued as government shutdown stretches into second week
LONDON - Eco Animal Health Group plc (AIM:EAH) announced Wednesday that Hafid Benchaoui, Head of Global R&D, will be leaving the company to pursue an opportunity in the companion animal health industry.
Benchaoui will remain with the company until October 21 to ensure an orderly transition of his responsibilities. The veterinary pharmaceutical company stated it is making good progress in recruiting a successor.
The company emphasized in its press release that all developments within its R&D pipeline remain on track, noting it continues to benefit from "a highly experienced senior R&D team."
Eco Animal Health, headquartered in the UK, specializes in developing and marketing veterinary pharmaceuticals globally, with a focus on antibiotics and vaccines for pigs and poultry. The company has marketing authorizations in over 70 countries and employs more than 200 people worldwide.
The company’s lead product is Aivlosin, a proprietary medication for treating respiratory and intestinal diseases in pigs and poultry.
David Hallas, Chief Executive Officer of Eco Animal Health, did not provide specific comments regarding Benchaoui’s departure in the announcement, though the board expressed gratitude for his contributions and wished him well in his future endeavors.
The company indicated it will provide further updates on the leadership transition in due course.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.